Aridis Pharmaceuticals (ARDS)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Sep 5, 2024 02:38 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Aridis Pharmaceuticals falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 5 | 19 | 8 | 21 |
Receivables | NA | 1 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 5 | 5 | 4 | 5 |
Total Current Assets | NA | 12 | 24 | 13 | 26 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 15 | 27 | 15 | 28 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 4 | 1 | 0 | 0 |
Accounts Payable | NA | 2 | 5 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 10 | 6 | 1 | 3 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 20 | 21 | 19 | 15 |
Total Current Liabilities | NA | 37 | 33 | 22 | 19 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 1 | 1 | 1 | 5 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 5 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 39 | 40 | 24 | 24 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 166 | 152 | 114 | 104 |
Retained Earnings | NA | -196 | -165 | -123 | -101 |
Other Equity | NA | 5 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -24 | -13 | -9 | 4 |
Total Liabilities & Shareholder's Equity | NA | 15 | 27 | 15 | 28 |
Total Common Equity | 0 | -24 | -13 | -9 | 4 |
Shares Outstanding | 45.30 | 20.80 | 14.00 | 10.00 | 8.90 |
Book Value Per Share | 0.00 | -1.16 | -0.94 | -0.87 | 0.41 |
Fiscal Year End for Aridis Pharmaceuticals falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | 0 | 0 |
Receivables | NA | NA | NA | 1 | 0 |
Notes Receivable | NA | NA | NA | 0 | 0 |
Inventories | NA | NA | NA | 0 | 0 |
Other Current Assets | NA | NA | NA | 4 | 4 |
Total Current Assets | NA | NA | NA | 4 | 4 |
Net Property & Equipment | NA | NA | NA | 1 | 1 |
Investments & Advances | NA | NA | NA | 0 | 0 |
Other Non-Current Assets | NA | NA | NA | 0 | 0 |
Deferred Charges | NA | NA | NA | 0 | 0 |
Intangibles | NA | NA | NA | 0 | 0 |
Deposits & Other Assets | NA | NA | NA | 1 | 1 |
Total Assets | NA | NA | NA | 7 | 6 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | 3 | 5 |
Accounts Payable | NA | NA | NA | 5 | 6 |
Current Portion Long-Term Debt | NA | NA | NA | 0 | 0 |
Current Portion Capital Leases | NA | NA | NA | 0 | 0 |
Accrued Expenses | NA | NA | NA | 8 | 8 |
Income Taxes Payable | NA | NA | NA | 0 | 0 |
Other Current Liabilities | NA | NA | NA | 0 | 0 |
Total Current Liabilities | NA | NA | NA | 17 | 20 |
Mortgages | NA | NA | NA | 0 | 0 |
Deferred Taxes/Income | NA | NA | NA | 0 | 0 |
Convertible Debt | NA | NA | NA | 0 | 0 |
Long-Term Debt | NA | NA | NA | 0 | 0 |
Non-Current Capital Leases | NA | NA | NA | 0 | 0 |
Other Non-Current Liabilities | NA | NA | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | NA | 0 | 0 |
Total Liabilities | NA | NA | NA | 18 | 21 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | 0 | 0 |
Common Stock (Par) | NA | NA | NA | 0 | 0 |
Capital Surplus | NA | NA | NA | 171 | 169 |
Retained Earnings | NA | NA | NA | -190 | -190 |
Other Equity | NA | NA | NA | 8 | 7 |
Treasury Stock | NA | NA | NA | 0 | 0 |
Total Shareholder's Equity | NA | NA | NA | -12 | -15 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | 7 | 6 |
Total Common Equity | 0 | 0 | 0 | -12 | -15 |
Shares Outstanding | 53.30 | 47.90 | 45.30 | 44.50 | 36.20 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | -0.27 | -0.41 |